|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
|
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | |||||||
| Deferred offering costs | |||||||
| Cash and cash equivalents held in trust account, interest income available for taxes | |||||||
| Accrued interest receivable held in trust account | |||||||
| Prepaid expenses | |||||||
| Total current assets | |||||||
| Cash and cash equivalents held in trust account, restricted | |||||||
| Total assets | |||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued expenses | |||||||
| Note payable to related party | |||||||
| Notes payable to related parties | |||||||
| Total current liabilities | |||||||
| Long term liabilities | |||||||
| Notes payable to related parties | |||||||
| Deferred underwriting fee | |||||||
| Total liabilities | |||||||
| Common stock, subject to possible redemption, 30,775,821 and 30,810,131 shares at redemption value at March 31, 2017 and December 31, 2016, respectively | |||||||
| Stockholders' equity | |||||||
| Preferred stock, $.0001 par value; 1,000,000 shares authorized; none issued and outstanding | |||||||
| Common stock, $.0001 par value; 120,000,000 shares authorized; 9,849,179 and 9,814,869 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively | |||||||
| Additional paid-in capital | |||||||
| Accumulated deficit | |||||||
| Total stockholders' equity | |||||||
| Total liabilities and stockholders’ equity |
Loading...